View Exam | PowerPak

1. Based on the recommendations from the 2021 American Diabetes Association Standards of Care, which of the following medications would be most appropriate for a person with type 2 diabetes and established cardiovascular because it has proven cardiovascular benefit? (LO 1)

A. Exenatide XR B. Sitagliptin C. Dulaglutide D. Ertugliflozin E. Unsure

2. Which of the following statements most accurately describes current guideline recommendations regarding the use of GLP-1 receptor agonists vs SGLT-2 inhibitors? (LO 1 and 2)

A. SGLT-2 inhibitors are preferred over GLP-1 receptor agonists in patients who are overweight B. SGLT-2 inhibitors are preferred over GLP-1 receptor agonists in patients with heart failure C. GLP-1 receptor agonists are preferred over SGLT-2 inhibitors in patients with established CVD D. GLP-1 receptor agonists are preferred over SGLT-2 inhibitors in patients with CKD E. Unsure

3. A 60-year-old woman has type 2 diabetes that is well controlled with metformin 1000 mg twice daily. Her current A1C is 6.9% and her goal A1C is less than 7% without hypoglycemia. She also has hypertension, dyslipidemia, peripheral neuropathy, and obesity. She has normal renal function and does not have albuminuria. She had a myocardial infarction 1 year ago. Which of the following plans is most appropriate to reduce her risk of diabetes-related complications? (LO 1 and 2)

A. Add a GLP-1 receptor agonist or SGLT-2 inhibitor to reduce her risk of CV events B. Do not add another diabetes medication since her A1C is below goal C. Add a GLP-1 receptor agonist or SGLT-2 inhibitor to reduce her risk of developing chronic kidney disease D. Change her A1C goal to less than 6.5% and add a DPP-4 inhibitor to prevent the progression of her peripheral neuropathy E. Unsure

4. A 55-year-old man has type 2 diabetes that is not optimally controlled on monotherapy metformin 1000 mg twice daily. He also has hypertension, dyslipidemia, peripheral vascular disease, and obesity. He tells you that he does not want to take injections because he doesn't like needles. Which of the following is the most appropriate next step? (LO 3)

A. Respect the person's wishes to not use an injection. Add a sulfonylurea since it is oral, inexpensive and effective. B. Ask him if he is willing to discuss his concerns about injection therapy with you. Utilize shared decision making to select an appropriate add-on medication based on patient characteristics, preferences, and goals. C. Explain to him that, since he has ASCVD, he needs to adhere to injection therapy or he is putting himself at risk of having a heart attack or stroke. D. Tell him that you understand. Explain that most people say they are afraid of needles, but most diabetics end up failing oral medications and eventually need injections to control their diabetes. E. Unsure

5. A 60-year-old man has type 2 diabetes that is not optimally controlled on metformin 1000 mg twice daily, empagliflozin 25 mg once daily, and Humalog 75/25 15 U in the morning and 10 U in the evening. His A1C is 8.3% and his goal is less than 7%. He tests his blood sugar twice daily and his readings indicate high fasting glucose levels with high variability. He is experiencing hypoglycemia 2 to 3 times per week. He also has hypertension, dyslipidemia, albuminuria, and peripheral neuropathy. He and his provider are discussing transitioning from mixed insulin to a once-weekly GLP-1 receptor agonist. Which of the following statements is most reasonable about this plan? (LO 2 and 3)

A. This plan is likely to achieve his A1C goal since once-weekly GLP-1 receptor agonists are significantly more effective at lowering A1C compared to mixed-insulin. B. He should stop the insulin completely on the first injection day of the once-weekly GLP-1 receptor agonist. C. Switching from mixed insulin to a once-weekly GLP-1 receptor agonist will allow him to stop monitoring his blood sugar immediately. D. Switching from mixed insulin to a once-weekly GLP-1 receptor agonist will lead to less injections per week and a lower risk of hypoglycemia. E. Unsure

Evaluation Questions

6. How confident are in your treatment choice for the 60-year-old man in question #5 above?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Based on the recommendations from the 2021 American Diabetes Association Standards of Care, which of the following medications would be most appropriate for a person with type 2 diabetes and established cardiovascular because it has proven cardiovascular benefit? (LO 1)

2. Which of the following statements most accurately describes current guideline recommendations regarding the use of GLP-1 receptor agonists vs SGLT-2 inhibitors? (LO 1 and 2)

Evaluation Questions

6. How confident are in your treatment choice for the 60-year-old man in question #5 above?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Based on the recommendations from the 2021 American Diabetes Association Standards of Care, which of the following medications would be most appropriate for a person with type 2 diabetes and established cardiovascular because it has proven cardiovascular benefit? (LO 1)

2. Which of the following statements most accurately describes current guideline recommendations regarding the use of GLP-1 receptor agonists vs SGLT-2 inhibitors? (LO 1 and 2)

Evaluation Questions

6. How confident are in your treatment choice for the 60-year-old man in question #5 above?

« Return to Activity

Customers who Purchased
this Activity also Purchased